Quarterly report [Sections 13 or 15(d)]

GOING CONCERN AND MANAGEMENTS LIQUIDITY PLANS (Details Narrative)

v3.26.3
GOING CONCERN AND MANAGEMENTS LIQUIDITY PLANS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 06, 2026
Apr. 02, 2026
Mar. 13, 2026
May 21, 2026
Feb. 15, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Mar. 04, 2025
Dec. 31, 2024
Common stock shares value           $ 150,000 $ 500,000 $ 665,000          
Working capital deficit                 $ (8,652,785)        
Cash               $ 287,688 18,233 $ 287,688 $ 139,360   $ 88,033
Net cash used in operating activities                 (1,052,875) (1,399,819)      
Gross Proceeds from issuance of promissory notes                 $ 404,904 947,700      
Promissory note outstanding $ 120,000       $ 100,000                
Common stock shares issued 336,323       294,118                
Common stock price per share $ 0.36       $ 0.34       $ 0.001   $ 0.001 $ 0.31  
Payment of notes payable - related party                 $ 14,500 $ 12,000      
March 1, 2024 [Member]                          
Description of funding                 The grant provides the Company with additional resources for the ongoing research of BICX104, a sustained release naltrexone implant for the treatment of methamphetamine use disorder. The grant provides for (i) $4,131,123 in funding during the first year, (ii) $3,638,268 during the second-year, and (iii) $3,260,586 during the third-year subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds        
Award granted by third party                 $ 11,029,977        
2026 Q1 Lucido Subscription Agreement [Member]                          
Common stock shares issued         1,470,588                
Common stock shares value         $ 500,000                
Common stock shares issued                 1,470,588        
Joseph Galligan [Member]                          
Common stock shares issued       375,000                  
Common stock shares value       $ 150,000                  
Unsecured Promissory Note Related Third Party [Member]                          
Amendment description   On April 2, 2026, the Company entered into a sixth amendment agreement to a promissory note, which was originally issued to a third party on December 8, 2023. In accordance with the amendment, the parties agreed to modify the maturity date of the note from March 31, 2026 to February 1, 2027. The principal amount due was increased by $30,000. In exchange for the modification, the Company issued 50,000 shares of restricted stock to the debt holder at $0.34 per share for a total value of $17,000. The promissory note bears interest at 5% per annum, and is convertible into common stock of the Company at a conversion price of $0.34 per share. During the nine months ended September 30, 2026, the Company made principal payments of $22,500. The balance outstanding as of September 30, 2026 was $324,950 On March 13, 2026, the Company entered into a sixth amendment agreement to a promissory note, which was originally issued to a third party on November 10, 2023. In accordance with the amendment, the parties agreed to modify the maturity date of the note from February 28, 2026 to September 30, 2026. The principal amount due was increased by $30,000. In exchange for the modification, the Company issued 50,000 shares of restricted stock to the debt holder at $0.40 per share for a total value of $20,000. During the nine months ended September 30, 2026, the Company made principal payments of $42,500. The balance outstanding as of September 30, 2026 was $273,352           On March 13, 2026, the Company entered into a fifth amendment agreement to a promissory note, which was originally issued to a third party on March 14, 2024. In accordance with the amendment, the parties agreed to modify the maturity date of the note from February 28, 2026 to September 30, 2026. The principal amount due was increased by $30,000. In exchange for the modification, the Company issued 50,000 shares of restricted stock to the debt holder at $0.40 per share for a total value of $20,000. During the nine months ended September 30, 2026, the Company made principal payments of $42,500. The balance outstanding as of September 30, 2026 was $273,352